AMRI Completes Strategic European Acquisition
News Mar 02, 2006
On January 30, AMRI announced the signing of a stock purchase agreement to acquire ComGenex. The completed acquisition provides AMRI with an immediate presence in Europe.
In combination with AMRI's facilities in the U.S. and Asia, the acquisition enhances the company's ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.
"All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE